JP7519358B2 - Mt1-mmpに特異的な二環式ペプチドリガンド - Google Patents
Mt1-mmpに特異的な二環式ペプチドリガンド Download PDFInfo
- Publication number
- JP7519358B2 JP7519358B2 JP2021533609A JP2021533609A JP7519358B2 JP 7519358 B2 JP7519358 B2 JP 7519358B2 JP 2021533609 A JP2021533609 A JP 2021533609A JP 2021533609 A JP2021533609 A JP 2021533609A JP 7519358 B2 JP7519358 B2 JP 7519358B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide ligand
- acid
- peptide
- mmp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being an antibiotic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1820288.7A GB201820288D0 (en) | 2018-12-13 | 2018-12-13 | Bicycle peptide ligaands specific for MT1-MMP |
| GB1820288.7 | 2018-12-13 | ||
| PCT/GB2019/053537 WO2020120981A1 (en) | 2018-12-13 | 2019-12-13 | Bicyclic peptide ligands specific for mt1-mmp |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512478A JP2022512478A (ja) | 2022-02-04 |
| JP2022512478A5 JP2022512478A5 (cg-RX-API-DMAC7.html) | 2022-12-19 |
| JP7519358B2 true JP7519358B2 (ja) | 2024-07-19 |
Family
ID=65146942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021533609A Active JP7519358B2 (ja) | 2018-12-13 | 2019-12-13 | Mt1-mmpに特異的な二環式ペプチドリガンド |
Country Status (14)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ731185A (en) | 2014-10-29 | 2024-03-22 | Bicyclerd Ltd | Bicyclic peptide ligands specific for mt1-mmp |
| EP3559018A1 (en) | 2016-12-23 | 2019-10-30 | Bicyclerd Limited | Peptide derivatives having novel linkage structures |
| WO2019002842A1 (en) | 2017-06-26 | 2019-01-03 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Cd137に対して特異的な二環式ペプチドリガンド |
| CA3091775A1 (en) | 2018-02-23 | 2019-08-29 | Bicycletx Limited | Multimeric bicyclic peptide ligands |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201820295D0 (en) * | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| EP3897849A1 (en) | 2018-12-21 | 2021-10-27 | BicycleTx Limited | Bicyclic peptide ligands specific for pd-l1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| CN116348476A (zh) | 2020-08-03 | 2023-06-27 | 拜斯科技术开发有限公司 | 基于肽的接头 |
| WO2023088236A1 (zh) * | 2021-11-16 | 2023-05-25 | 海思科医药集团股份有限公司 | Mt1-mmp的双环肽配体及其缀合物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016067035A1 (en) | 2014-10-29 | 2016-05-06 | Bicycle Therapeutics Limited | Bicyclic peptide ligands specific for mt1-mmp |
| WO2018127699A1 (en) | 2017-01-06 | 2018-07-12 | Bicyclerd Limited | Compounds for treating cancer |
Family Cites Families (194)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2642514A (en) | 1946-08-10 | 1953-06-16 | American Cyanamid Co | Ion exchange process with magnetic ion exchange resins |
| GB1239978A (en) | 1968-07-15 | 1971-07-21 | Permutt Company Ltd | Ion-exchange processes |
| US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| EP0941120A4 (en) | 1996-11-05 | 2004-08-18 | Bristol Myers Squibb Co | BRANCHED PEPTIDLINKERS |
| US6410275B1 (en) | 1997-05-02 | 2002-06-25 | Biomerieux, Inc. | Disposable test devices for performing nucleic acid amplification reactions |
| US6326144B1 (en) | 1998-09-18 | 2001-12-04 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
| WO2000029617A2 (en) | 1998-09-24 | 2000-05-25 | Advanced Research And Technology Institute, Inc. | Water-soluble luminescent quantum dots and bioconjugates thereof |
| US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
| OA12118A (en) | 1999-12-10 | 2006-05-04 | Pfizer Prod Inc | PyrroloÄ2,3-dÜpyrimidine compounds. |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| KR100833371B1 (ko) | 2001-04-27 | 2008-05-28 | 젠야쿠코교가부시키가이샤 | 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제 |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| AU2003217606C1 (en) | 2002-02-21 | 2008-07-17 | Institute Of Virology | Soluble Form of Carbonic Anhydrase IX (s-CA IX), Assays to Detect s-CA IX, CA IXs Coexpression with HER-2/neu/c-erbB-2 and CA IX-Specific Monoclonal Antibodies to Non-Immunodominant Epitopes |
| MXPA05001766A (es) | 2002-08-14 | 2005-08-19 | Atugen Ag | Uso de proteina quinasa n beta. |
| KR20050091716A (ko) | 2002-12-12 | 2005-09-15 | 텔 아비브 유니버시티 퓨쳐 테크놀로지 디벨롭먼트 엘.피. | 글리코겐 신타제 키나제-3 억제제 |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| WO2004089925A1 (en) | 2003-04-03 | 2004-10-21 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| WO2005007623A2 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| EP2915820A1 (en) | 2004-02-06 | 2015-09-09 | MorphoSys AG | Anti-CD38 human antibodies and uses therefor |
| CA2505655C (en) | 2004-04-28 | 2013-07-09 | Warren Chan | Stable, water-soluble quantum dot, method of preparation and conjugates thereof |
| LT2612862T (lt) | 2004-05-13 | 2017-01-25 | Icos Corporation | Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| ES2428869T3 (es) | 2005-01-24 | 2013-11-12 | Pepscan Systems B.V. | Compuestos de unión, compuestos inmunógenos y peptidomiméticos |
| US7989590B2 (en) | 2005-03-22 | 2011-08-02 | Rohto Pharmaceutical Co., Ltd | Peptides that increase collagen or hyaluronic acid production |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール,インク. | Gitr結合分子およびその使用 |
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| KR20080080482A (ko) | 2005-09-07 | 2008-09-04 | 메디뮨 엘엘씨 | 독소가 컨쥬게이트된 eph 수용체 항체 |
| HRP20140975T1 (hr) | 2005-10-07 | 2014-11-21 | Exelixis, Inc. | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| WO2007093836A1 (en) | 2006-02-13 | 2007-08-23 | Cellectis | Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof |
| KR101533461B1 (ko) | 2006-04-26 | 2015-07-02 | 에프. 호프만-라 로슈 아게 | Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체 |
| US7666392B2 (en) | 2006-09-15 | 2010-02-23 | Siemens Medical Solutions Usa, Inc. | Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| CN101232326B (zh) | 2007-01-22 | 2012-01-11 | 中兴通讯股份有限公司 | 用于无源光网络系统的动态带宽分配装置及其实现方法 |
| HUE029188T2 (en) | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US20090110662A1 (en) | 2007-04-30 | 2009-04-30 | Intezyne Technologies, Inc. | Modification of biological targeting groups for the treatment of cancer |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| CN101918844A (zh) | 2007-06-18 | 2010-12-15 | 米迪缪尼有限公司 | 表达epha2和erbb2的细胞的协同治疗 |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| CN101497878B (zh) | 2008-01-30 | 2012-11-07 | 房学迅 | 特异性高效亲和膜ⅰ型基质金属蛋白酶(mt1-mmp)的多肽、蛋白及其应用 |
| JP6074574B2 (ja) | 2008-02-05 | 2017-02-08 | バイシクル セラピューティクス リミテッド | 方法及び組成物 |
| PT2257309T (pt) | 2008-02-27 | 2020-01-22 | Yeda Res And Development Company Ltd | Conjugados rgd-(bacterio)clorofila para utilização no diagnóstico de tumores compreendendo domínios necróticos |
| MY165582A (en) | 2008-03-11 | 2018-04-05 | Incyte Holdings Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| US8293714B2 (en) | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
| FR2932189A1 (fr) | 2008-06-10 | 2009-12-11 | Commissariat Energie Atomique | Biopuces pour la detection de l'activite enzymatique d'une enzyme protease |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
| CA2769444A1 (en) | 2009-05-19 | 2010-11-25 | Aic Blab Company | Composite current collector and methods therefor |
| GB0914110D0 (en) | 2009-08-12 | 2009-09-16 | Medical Res Council | Peptide libraries |
| IN2015DN02826A (cg-RX-API-DMAC7.html) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| AU2010321738B2 (en) | 2009-11-23 | 2016-07-14 | Palatin Technologies, Inc. | Melanocortin-1 receptor-specific cyclic peptides |
| DK2510010T3 (en) | 2009-12-10 | 2015-12-14 | Hoffmann La Roche | Antibodies that bind to human CSF1R extracellular domain 4 and their use |
| US9073974B2 (en) | 2009-12-21 | 2015-07-07 | The Regents Of The University Of California | RGD-containing cyclic peptides |
| EP2343081A1 (en) | 2009-12-31 | 2011-07-13 | Rijksuniversiteit Groningen | Interferon analogs |
| JP2013518807A (ja) | 2010-02-04 | 2013-05-23 | メディカル リサーチ カウンシル | 多重特異性ペプチド |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| RU2617971C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| EP3943154A1 (en) | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| WO2012057624A1 (en) | 2010-10-25 | 2012-05-03 | Pepscan Systems B.V. | Novel bicyclic peptide mimetics |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US20130072598A1 (en) | 2011-03-18 | 2013-03-21 | Board Of Regents Of The University Of Nebraska | Thermoplastics from Distillers Dried Grains and Feathers |
| NO2694640T3 (cg-RX-API-DMAC7.html) | 2011-04-15 | 2018-03-17 | ||
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| JP6254527B2 (ja) | 2011-10-07 | 2017-12-27 | バイサイクル・セラピューティクス・リミテッド | 構造化ポリペプチドの特異性のモジュレーション |
| GB201117428D0 (en) | 2011-10-07 | 2011-11-23 | Bicycle Therapeutics Ltd | Structured polypeptides with sarcosine linkers |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| US9670521B2 (en) | 2012-09-24 | 2017-06-06 | Medimmune Limited | Amino acid derivatives |
| US9587001B2 (en) | 2012-10-19 | 2017-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | Conjugated knottin mini-proteins containing non-natural amino acids |
| CN111363047A (zh) | 2013-03-12 | 2020-07-03 | 分子模板公司 | 用于引起细胞内化的cd20结合免疫毒素及其使用方法 |
| US20140274759A1 (en) | 2013-03-15 | 2014-09-18 | Bicycle Therapeutics Limited | Modification of polypeptides |
| JP6197865B2 (ja) | 2013-03-15 | 2017-09-20 | 日本ゼオン株式会社 | 中空重合体粒子の水性分散液およびその製造方法 |
| US10233249B2 (en) | 2013-03-19 | 2019-03-19 | Beijing Shenogen Pharma Group Ltd. | Antibodies and methods for treating estrogen receptor-associated diseases |
| GB201306623D0 (en) | 2013-04-11 | 2013-05-29 | Bicycle Therapeutics Ltd | Modulation of structured polypeptide specificity |
| ES2705068T3 (es) | 2013-05-23 | 2019-03-21 | Ohio State Innovation Foundation | Síntesis química y cribado de bibliotecas de péptidos bicíclicos |
| KR20250051130A (ko) | 2013-09-25 | 2025-04-16 | 싸이톰스 테라퓨틱스, 인크. | 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
| WO2015063465A2 (en) | 2013-10-28 | 2015-05-07 | Bicycle Therapeutics Limited | Novel polypeptides |
| DK3102576T3 (da) | 2014-02-03 | 2019-07-22 | Vitae Pharmaceuticals Llc | Dihydropyrrolopyridininhibitorer af ror-gamma |
| AU2015255883A1 (en) | 2014-05-08 | 2016-10-27 | Novodiax, Inc. | Direct immunohistochemistry assay |
| PT3149025T (pt) | 2014-05-21 | 2019-08-01 | Entrada Therapeutics Inc | Peptídeos penetrantes de células e métodos de fabrico e utilização dos mesmos |
| GB201416960D0 (en) | 2014-09-25 | 2014-11-12 | Antikor Biopharma Ltd | Biological materials and uses thereof |
| US10654897B2 (en) | 2014-09-30 | 2020-05-19 | Polyphor Ag | β-hairpin peptidomimetics |
| CA2963556C (en) | 2014-10-24 | 2023-03-14 | Research Corporation Technologies, Inc. | Small antibody-like polypeptides that bind to epha2 receptor |
| CA2966005C (en) | 2014-10-31 | 2021-04-27 | Abbvie Biotherapeutics Inc. | Anti-cs1 antibodies and antibody drug conjugates |
| EP3903826B1 (en) | 2014-12-04 | 2024-05-08 | Celgene Corporation | Biomolecule conjugates |
| IL237525A (en) | 2015-03-03 | 2017-05-29 | Shalom Eli | Method for labeling a prostate-specific membrane antigen with a radioactive isotope |
| CN107529836A (zh) | 2015-04-22 | 2018-01-02 | 三井化学株式会社 | 具有关节用支撑体部的衣物、及膝用支撑体 |
| WO2016171242A1 (ja) | 2015-04-24 | 2016-10-27 | 第一三共株式会社 | Epha2の検出 |
| JP2018521960A (ja) | 2015-04-28 | 2018-08-09 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) | 酵素で活性化された第XII因子(FXIIa)の新規阻害剤 |
| JP7366518B2 (ja) | 2015-05-06 | 2023-10-23 | ヤンセン バイオテツク,インコーポレーテツド | 前立腺特異的膜抗原結合フィブロネクチンiii型ドメイン |
| EP3115066A1 (en) | 2015-07-07 | 2017-01-11 | Technische Universität München | Novel psma-specific binding proteins |
| US9963495B2 (en) | 2015-10-27 | 2018-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Polypeptides targeting vascular endothelial growth factor receptor and prostate specific membrane antigen |
| EP3181146A1 (en) | 2015-12-16 | 2017-06-21 | Ruprecht-Karls-Universität Heidelberg | Cyclic ntcp-targeting peptides and their uses as entry inhibitors |
| GB201600911D0 (en) * | 2016-01-18 | 2016-03-02 | Bicycle Therapeutics Ltd | Stabilized peptide derivatives |
| US10765625B2 (en) | 2016-03-15 | 2020-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | Knottin-drug conjugates and methods of using the same |
| JP2019512477A (ja) | 2016-03-16 | 2019-05-16 | メリマック ファーマシューティカルズ インコーポレーティッド | エフリン受容体a2(epha2)のナノリポソーム標的化及び関連する診断 |
| KR102775461B1 (ko) | 2016-04-01 | 2025-02-28 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩타이드 조성물 및 이의 용도 |
| MX2018012803A (es) | 2016-04-20 | 2019-06-24 | Hangzhou Dac Biotech Co Ltd | Derivados de las toxinas de amanita y su conjugacion a una molecula de union celular. |
| BR112018071612A2 (pt) | 2016-04-22 | 2019-02-19 | Alligator Bioscience Ab | polipeptídeos biespecíficos inovadores contra cd137 |
| GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| KR20190014525A (ko) | 2016-05-27 | 2019-02-12 | 애브비 바이오테라퓨틱스 인크. | 면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질 |
| WO2018096365A1 (en) | 2016-11-27 | 2018-05-31 | Bicyclerd Limited | Methods for treating cancer |
| MX2019007367A (es) | 2016-12-23 | 2020-01-27 | Bicycletx Ltd | Ligandos de peptido para enlace a mt1-mmp. |
| EP3559018A1 (en) | 2016-12-23 | 2019-10-30 | Bicyclerd Limited | Peptide derivatives having novel linkage structures |
| BR112019017628A2 (pt) | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição |
| GB201706477D0 (en) | 2017-04-24 | 2017-06-07 | Bicycle Therapeutics Ltd | Modification of polypeptides |
| EP3615550A1 (en) | 2017-04-27 | 2020-03-04 | BicycleTx Limited | Bicyclic peptide ligands and uses thereof |
| WO2018222987A1 (en) | 2017-06-01 | 2018-12-06 | Tarveda Therapeutics, Inc. | Targeted constructs |
| WO2019002842A1 (en) | 2017-06-26 | 2019-01-03 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Cd137に対して特異的な二環式ペプチドリガンド |
| WO2019034866A1 (en) | 2017-08-14 | 2019-02-21 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF |
| WO2019034868A1 (en) | 2017-08-14 | 2019-02-21 | Bicyclerd Limited | CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| CA3247730A1 (en) | 2017-11-07 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Hydrophilic linkers for antibody drug conjugates |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| US11572370B2 (en) | 2018-01-08 | 2023-02-07 | Biohaven Therapeutics Ltd. | CD16A binding agents and uses thereof |
| CA3091775A1 (en) | 2018-02-23 | 2019-08-29 | Bicycletx Limited | Multimeric bicyclic peptide ligands |
| CA3095582A1 (en) | 2018-04-04 | 2019-10-10 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
| CN112384534A (zh) | 2018-05-21 | 2021-02-19 | 指南针制药有限责任公司 | 用于增强nk细胞对靶细胞的杀死的组合物和方法 |
| GB201810320D0 (en) | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to CD38 |
| GB201810325D0 (en) | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to PSMA |
| GB201810329D0 (en) | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to integrin avB3 |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| GB201810327D0 (en) | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to IL-17 |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| WO2020084305A1 (en) | 2018-10-23 | 2020-04-30 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| CA3116504A1 (en) | 2018-10-30 | 2020-05-07 | Bicyclerd Limited | Bt1718 for use in treating cancer |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| SG11202106081YA (en) | 2018-12-13 | 2021-07-29 | Bicycletx Ltd | Bicyclic peptide ligands specific for mt1-mmp |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| JP7728701B2 (ja) | 2018-12-17 | 2025-08-25 | レビトープ リミテッド | 双子型免疫細胞エンゲージャー |
| EP3897849A1 (en) | 2018-12-21 | 2021-10-27 | BicycleTx Limited | Bicyclic peptide ligands specific for pd-l1 |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| US10882987B2 (en) | 2019-01-09 | 2021-01-05 | Nova Chemicals (International) S.A. | Ethylene interpolymer products having intermediate branching |
| GB201900525D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for caix |
| GB201900526D0 (en) | 2019-01-15 | 2019-03-06 | Bicyclerd Ltd | Bicyclic peptide ligands specific for caix |
| GB201900527D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for integrin avb3 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| GB201900528D0 (en) | 2019-01-15 | 2019-03-06 | Bicyclerd Ltd | Bicyclic peptide ligands specific for integrin AVB3 |
| GB201900530D0 (en) | 2019-01-15 | 2019-03-06 | Bicyclerd Ltd | Bicyclic peptide ligands specific for CD38 |
| WO2020165600A1 (en) | 2019-02-14 | 2020-08-20 | Bicycletx Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
| WO2020178574A1 (en) | 2019-03-04 | 2020-09-10 | Bicyclerd Limited | Synthesis of bicycle toxin conjugates, and intermediates thereof |
| US20220184222A1 (en) | 2019-04-02 | 2022-06-16 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
| KR20220007098A (ko) | 2019-05-09 | 2022-01-18 | 바이사이클티엑스 리미티드 | Ox40에 특이적인 이환식 펩티드 리간드 |
| TWI869398B (zh) | 2019-05-10 | 2025-01-11 | 英商拜西克爾德有限公司 | 治療癌症之方法 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| US20220275053A1 (en) | 2019-08-13 | 2022-09-01 | Bicycletx Limited | Modified multimeric bicyclic peptide ligands |
| GB201912320D0 (en) | 2019-08-28 | 2019-10-09 | Bicycletx Ltd | PBP Binding Bicyclic Peptide Ligands |
| SI4464721T1 (sl) | 2019-10-03 | 2025-08-29 | Bicycletx Limited | Heterotandemski biciklični peptidni kompleksi |
| GB201914872D0 (en) | 2019-10-15 | 2019-11-27 | Bicycletx Ltd | Bicyclic peptide ligand drug conjugates |
| EP4045075A1 (en) | 2019-10-16 | 2022-08-24 | Bicyclerd Limited | Methods for treating cancer |
| CN114760988A (zh) | 2019-11-27 | 2022-07-15 | 拜斯科技术开发有限公司 | 对EphA2具有特异性的双环肽配体和其用途 |
| IT202000001231A1 (it) | 2020-01-22 | 2021-07-22 | Celery S R L | Nuovi ceppi di batteri lattici, composizione alimentare che li comprende, preparazione di tale composizione |
| GB202002706D0 (en) | 2020-02-26 | 2020-04-08 | Bicycletx Ltd | Pbp3 binding bicyclic peptide ligands |
| GB202002705D0 (en) | 2020-02-26 | 2020-04-08 | Bicycletx Ltd | Anti-infective bicyclic peptide conjugates |
| AU2021276616A1 (en) | 2020-05-20 | 2023-01-05 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 and uses thereof |
| EP4165414A1 (en) | 2020-06-12 | 2023-04-19 | BicycleTX Limited | Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2) |
| CN116348476A (zh) | 2020-08-03 | 2023-06-27 | 拜斯科技术开发有限公司 | 基于肽的接头 |
| WO2022038158A1 (en) | 2020-08-17 | 2022-02-24 | Bicycletx Limited | Bicycle conjugates specific for nectin-4 and uses thereof |
| AU2022206394A1 (en) | 2021-01-08 | 2023-08-24 | Bicycletx Limited | Bicyclic peptide ligands specific for nk cells |
| CA3206529A1 (en) | 2021-01-08 | 2022-07-14 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
| JP2024504068A (ja) | 2021-01-08 | 2024-01-30 | バイスクルテクス・リミテッド | 抗感染性二環式ペプチドリガンド |
| US20250186539A2 (en) | 2021-01-11 | 2025-06-12 | Bicycletx Limited | Methods for treating cancer |
| WO2023031623A2 (en) | 2021-09-03 | 2023-03-09 | Bicycletx Limited | Synthesis of bicycle toxin conjugates, and intermediates thereof |
| CN118475345A (zh) | 2021-11-16 | 2024-08-09 | 拜斯科技术开发有限公司 | 治疗癌症的方法 |
-
2018
- 2018-12-13 GB GBGB1820288.7A patent/GB201820288D0/en not_active Ceased
-
2019
- 2019-12-13 SG SG11202106082TA patent/SG11202106082TA/en unknown
- 2019-12-13 WO PCT/GB2019/053537 patent/WO2020120981A1/en not_active Ceased
- 2019-12-13 CA CA3122659A patent/CA3122659A1/en active Pending
- 2019-12-13 IL IL283874A patent/IL283874B2/en unknown
- 2019-12-13 JP JP2021533609A patent/JP7519358B2/ja active Active
- 2019-12-13 KR KR1020217021607A patent/KR20210123296A/ko active Pending
- 2019-12-13 MX MX2021006989A patent/MX2021006989A/es unknown
- 2019-12-13 CN CN201980081542.7A patent/CN113474047B/zh active Active
- 2019-12-13 US US17/309,631 patent/US12350343B2/en active Active
- 2019-12-13 BR BR112021011217-0A patent/BR112021011217A2/pt unknown
- 2019-12-13 EA EA202191651A patent/EA202191651A1/ru unknown
- 2019-12-13 EP EP19824379.2A patent/EP3894009A1/en active Pending
- 2019-12-13 AU AU2019398722A patent/AU2019398722B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016067035A1 (en) | 2014-10-29 | 2016-05-06 | Bicycle Therapeutics Limited | Bicyclic peptide ligands specific for mt1-mmp |
| WO2018127699A1 (en) | 2017-01-06 | 2018-07-12 | Bicyclerd Limited | Compounds for treating cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021006989A (es) | 2021-10-13 |
| IL283874B1 (en) | 2025-05-01 |
| CN113474047A (zh) | 2021-10-01 |
| CA3122659A1 (en) | 2020-06-18 |
| SG11202106082TA (en) | 2021-07-29 |
| US20220362390A1 (en) | 2022-11-17 |
| AU2019398722B2 (en) | 2025-09-04 |
| US12350343B2 (en) | 2025-07-08 |
| JP2022512478A (ja) | 2022-02-04 |
| WO2020120981A1 (en) | 2020-06-18 |
| KR20210123296A (ko) | 2021-10-13 |
| AU2019398722A1 (en) | 2021-08-05 |
| BR112021011217A2 (pt) | 2021-08-31 |
| IL283874A (en) | 2021-07-29 |
| EP3894009A1 (en) | 2021-10-20 |
| EA202191651A1 (ru) | 2021-09-13 |
| GB201820288D0 (en) | 2019-01-30 |
| IL283874B2 (en) | 2025-09-01 |
| CN113474047B (zh) | 2025-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12350343B2 (en) | Bicyclic peptide ligands specific for MT1-MMP | |
| US12491253B2 (en) | Bicyclic peptide ligands specific for MT1-MMP | |
| AU2019398516B2 (en) | Bicyclic peptide ligands specific for MT1-MMP | |
| JP7645801B2 (ja) | Cd38に特異的な二環式ペプチドリガンド | |
| JP7658902B2 (ja) | Pd-l1に特異的な二環式ペプチドリガンド | |
| JP2025020121A (ja) | Pd-l1に特異的な二環式ペプチドリガンド | |
| CA3154672A1 (en) | Bicyclic peptide ligand drug conjugates | |
| JP2025011099A (ja) | Psmaに特異的な二環式ペプチドリガンド | |
| WO2020148525A1 (en) | Bicyclic peptide ligands specific for caix | |
| EP3966233A1 (en) | Bicyclic peptide ligands specific for integrin alpha v beta 3 | |
| US20220008545A1 (en) | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR FAPa | |
| EA046810B1 (ru) | Бициклические пептидные лиганды, специфичные к mt1-mmp | |
| EA046487B1 (ru) | Бициклические пептидные лиганды, специфичные к mt1-mmp |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210928 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221209 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221209 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231124 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231128 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240227 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240514 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240520 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240708 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7519358 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |